MOBILE, Ala. / Jun 05, 2023 / Business Wire / CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced that Chris Fowler, President and Chief Executive Officer, and Matt Chambless, Chief Financial Officer, will participate in the Stifel 2023 Cross Sector Insight Conference being held June 6-7, 2023, in Boston, Massachusetts.
In connection with the conference, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, https://investors.cpsi.com, starting at 9:45 a.m. Eastern Time /8:45 a.m. Central Time on Wednesday, June 7, 2023.
About CPSI
CPSI has over four decades of experience in connecting providers, patients and communities with innovative solutions that support both the clinical and financial side of healthcare delivery. We provide business, consulting, and managed information technology (IT) services, including our industry leading HFMA Peer Reviewed® suite of revenue cycle management (RCM) offerings, to help streamline day-to-day revenue functions, enhance productivity, and support the financial health of healthcare organizations. Our patient engagement solutions provide patients and providers with the critical information and tools they need to share existing clinical data and analytics that support value-based care, improve outcomes, and increase patient satisfaction. We support efficient patient care across an expansive base of community hospitals and post-acute care facilities with electronic health record (EHR) product offerings that successfully integrate data between care settings. We make healthcare accessible through data-driven insights that support informed decisions and deliver workflow efficiencies, while keeping patients at the center of care. We are a healthcare solutions company. We clear the way for care. For more information, please visit www.cpsi.com.
Last Trade: | US$24.31 |
Daily Change: | 0.18 0.75 |
Daily Volume: | 138,990 |
Market Cap: | US$362.950M |
March 10, 2025 February 12, 2025 February 11, 2025 January 30, 2025 January 02, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load